CANDEL THERAP.INC. DL-,01

Candel Therapeutics said at the Cantor Fitzgerald Healthcare Conference that aglatimogen met the primary endpoint of disease‑free survival in a phase‑III study of 745 patients (hazard ratio 0.7; ~30% improvement). At the 2‑year biopsy, pathologic complete response was 80% versus 63% in the control group. The FDA has granted RMAT status and confirmed the Special Protocol Assessment; a BLA submission is planned for late 2025, with manufacturing, analytical comparability and biomarker studies driving the tight timeline. Candel also noted ongoing programs in lung cancer, pancreatic cancer and glioblastoma. » Więcej na de.investing.com

Candel Therapeutics’ stock rose to a 52‑week high of $13.96 and is currently trading around $13.93, implying a market capitalization of about $1.06 billion. The shares have gained substantially year‑to‑date (roughly +125–132% according to data), and InvestingPro sees the stock near its fair value. Candel has initiated the global phase‑III AURORA study of aglatimagene besadenovec in metastatic non‑small cell lung cancer; analysts raised price targets and reiterated buy ratings. Mark Sims was also appointed chief commercial officer; the company is targeting a Biologics License Application submission for the therapy by the end of 2026. » Więcej na de.investing.com

Candel Therapeutics reports pivotal phase‑3 PrTK03 data showing a significant improvement in disease‑free survival for aglatimagene besadenovec in localized prostate cancer. In parallel, the phase‑3 AURORA study was launched. Stifel initiated coverage of the stock with a 'Buy' rating and a $22 price target. » Więcej na finanzen.net